Compare ITGR & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITGR | VERA |
|---|---|---|
| Founded | 1970 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.5B |
| IPO Year | 2000 | 2021 |
| Metric | ITGR | VERA |
|---|---|---|
| Price | $90.98 | $34.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $91.14 | $81.30 |
| AVG Volume (30 Days) | 417.0K | ★ 1.0M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $1,853,637,000.00 | N/A |
| Revenue This Year | $1.69 | N/A |
| Revenue Next Year | $6.53 | $472.48 |
| P/E Ratio | $191.88 | ★ N/A |
| Revenue Growth | ★ 7.98 | N/A |
| 52 Week Low | $62.00 | $19.07 |
| 52 Week High | $123.78 | $56.05 |
| Indicator | ITGR | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 53.52 | 49.25 |
| Support Level | $82.58 | $32.48 |
| Resistance Level | $106.08 | $42.77 |
| Average True Range (ATR) | 2.45 | 2.31 |
| MACD | -0.02 | 0.19 |
| Stochastic Oscillator | 48.79 | 54.40 |
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns maximum of its revenue in the United States, and also has its presence in Ireland, Puerto Rico, Costa Rica, and Rest of the World.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.